Introduction
============

Brain injury includes several conditions that damage the brain and alter its function, such as trauma, stroke, hypoxia, and infection. Although this term generally refers to sudden insults, neurodegenerative disorders are also sources of brain damage ([@B47]). There are still no effective treatments for most cases of brain injury and numerous gaps regarding their physiopathology. However, research has elucidated the possible detrimental effects of the inflammatory response mediated by glial cells. If this response is uncontrolled and chronic, it may lead to neurotoxicity ([@B6]) and disruption of endogenous neurogenesis ([@B99]). This phenomenon known as *neuroinflammation* is also evident in the aging brain, which is particularly vulnerable to neurodegenerative and neuropsychiatric disease ([@B52]; [@B55]). Therefore, neuroinflammation is a key target for neuroprotection and repair ([@B86], [@B87]), which constitutes a promising alternative for brain injury and neurological disorders.

*N*-acylethanolamides (NAEs) are endogenous lipid mediators which apparently elicit a pro-homeostatic role in response to neuroinflammation ([@B22]; [@B86]). In addition, exogenous administration of NAEs could exert neuroprotective effects by reducing neuroinflammation, as it has been demonstrated in several models of β-amyloid- induced astrogliosis ([@B80], [@B83]; [@B7]), Alzheimer disease ([@B15]; [@B82]), Parkinson disease ([@B27]; [@B23]; [@B32]), stroke ([@B2]), cerebral ischemia ([@B102]), traumatic brain injury ([@B1]), spinal cord injury (SCI) ([@B29]; [@B24]), peripheral neuropathy ([@B51]) and lipopolysaccharide (LPS)-induced neuroinflammation ([@B78]). The aim of this review is to provide an overview of recent progress related to the endogenous and exogenous neuroprotective and anti-inflammatory properties of NAEs, emphasizing their effects on glial cells.

Astrocytes, Microglia, and Neuroinflammation
============================================

Astrocytes contribute to maintain homeostasis in the central nervous system (CNS) by providing nutrients to neurons, recycling neurotransmitters and regulating synaptic plasticity ([@B64]). Astrocytes also have a critical role in the regulation of neural immune response and neuronal survival, promoting wound healing and tissue repair upon CNS insults ([@B97]; [@B40]). Modifications in gene expression, hypertrophy and proliferation of astrocytes are involved in preserving neuronal function ([@B89]). Microglia also responds to brain injury. It constitutes the resident macrophage population of the CNS ([@B34]; [@B52]) that migrates to the injury site and initiates communication with the immune system ([@B70]). While astrocytes monitor extracellular fluid, pH and ion homeostasis in order to promote the recovery of injured tissue, microglia scavenges dead cells, and secretes neurotrophic factors. This process is known as *reactive gliosis* ([@B87]), and is characterized by molecular, morphological and functional changes in glial phenotype in response to brain injury ([@B101]; [@B64]).

Cytokines mediate communication between nervous and immune system ([@B86], [@B87]), which is known as *neuroimmunomodulation* ([@B6]). Therefore, besides generating pro-inflammatory molecules, glial cells respond to pro-inflammatory signals released from mast cells ([@B84]), and cytokines recruit glia to the focus of inflammation ([@B21]; [@B69]; [@B75]).

However, if glial activation is excessive, the inflammatory response oriented to protect neural tissue might override the bounds of physiological control ([@B86], [@B87]) and reactive gliosis becomes dysfunctional ([@B64]). This phenomenum called *neuroinflammation* leads to neurotoxicity and promotes further injury ([@B6]). While acute insults are transient and rarely detrimental to neuronal survival, neuroinflammation is a chronic and self-perpetuating response, which may constitute a point of origin for neurological disorders ([@B40]). Non-resolving inflammation is a major cause of disease since inflammation can damage tissue and necrosis can exacerbate inflammation ([@B59]). Moreover, uncontrolled inflammation promotes disruption of endogenous neurogenesis ([@B99]) and synaptic dysfunction ([@B13]), inhibiting adaptive plasticity mechanisms needed for functional recovery ([@B64]).

Genes mediating neuroinflammation and immune system activation show significant age-related upregulation ([@B55]). Aging acts as a *silent contributor* to neuroinflammation, establishing the condition as a central pathophysiological mechanism, maintaining, and impairing it ([@B76]). Reactive gliosis and neuroinflammation may be triggered by the accumulation of proteins with abnormal conformations (e.g., β-amyloid) or by signals emanating from brain injury processes (e.g., hypoperfusion of neural tissue) in the aging brain ([@B33]; [@B80]).

The aging brain is characterized by a sensitization to neuroinflammatory responses, which provokes abnormalities in brain structure and metabolism ([@B73]). Aged microglia is primed to be activated and resistant to endogenous regulatory systems ([@B60]). Hence, the response of microglia to stimulus involves a more robust and persistent production of pro-inflammatory cytokines, which compromises normal neuronal functionality ([@B11]; [@B65]). Microglia develops a loss of integrated regulatory networks. Therefore, homeostasis in brain-immune interactions is considerably altered and reduced. This neuro-immune dysfunction is associated with a low-grade chronic neuroinflammation, which contributes to cognitive deficits and susceptibility to age-related pathologies ([@B52]): neurodegenerative and neuropsychiatric diseases ([@B55]).

Neuroinflammation represents a key element in brain aging ([@B52]; [@B55]) and in the pathophysiology of several neurological diseases ([@B87], [@B85]): neurodegenerative disorders ([@B30]; [@B16]; [@B53]; [@B5]), stroke ([@B38]), chronic neuropathic pain ([@B57]; [@B92]), among others. Therefore, neuroinflammation constitutes an important target for neuroprotection ([@B86], [@B87]). Although mechanisms of neuroinflammation are probably similar in aging and a wide range of neurological diseases, these conditions differ in etiology and in how the inflammatory response contributes to progressive damage. A thorough understanding of these molecular pathways is necessary for designing neuroprotective strategies ([@B76]).

The *N*-acylethanolamides Signaling System
==========================================

*N*-acylethanolamides are present in human and murine brain in considerable amounts ([@B19]; [@B48], [@B49]). NAEs are endogenous lipid mediators that include the endocannabinoid *N-arachidonoylethanolamide (anandamide or AEA)* and its congeners, the non-cannabimimmetic compounds *Palmitoylethanolamide (PEA)* and *Oleoylethanolamide (OEA)* ([@B86]; [@B78]) (**Figure [1](#F1){ref-type="fig"}**). AEA is synthesized by the hydrolysis of *N-acylphosphatidyletanolamide (NAPE)*, through the action of the enzyme *N-acylphosphatidylethanolamide-phospholipase D (NAPE-PLD)*. After performing in CB1 and CB2 receptors, AEA is degraded by the action of the enzyme *fatty acid amidohydrolase (FAAH).* AEA is also synthesized from ethanolamide and a fatty acid (arachidonic acid) (**Figure [2](#F2){ref-type="fig"}**). AEA is a transient signal synthesized on demand, from changes in cell membrane induced by stimulating glutamatergic, GABAergic, cholinergic, or dopaminergic receptors. This transient signal can act as a retrograde or anterograde messenger, either by inhibiting neurotransmitter release on presynaptic CB1 or by controlling postsynaptic depolarization ([@B67]; [@B71]) (**Figure [2](#F2){ref-type="fig"}**).

![**Structural formulas for *N*-acylethanolamides (NAEs)**.](fnagi-08-00081-g001){#F1}

![**Role of synthesis and catalysis of *N*-acylethanolamides (NAEs) on the synaptic transmission.** Anandamide (AEA) is synthesized when *N*-acylphosphatidyletanolamide (NAPE) is hydrolysed by a specific phospholipase D (PLD*)*. AEA is also synthesized from arachidonic acid (AA) and ethanolamide. When AA is replaced by palmitic acid (PA) or oleic acid (OA), Palmitoylethanolamide (PEA), or Oleoylethanolamide (OEA) are synthesized respectively. PA and OA are AA conjugates with other compounds, and therefore PEA and OEA are considered as AEA derivatives. AEA contributes to bioelectrical plasticity, by acting as a retrograde, or anterograde messenger. After performing in CB1 and CB2 receptors, AEA is catalyzed by fatty acid amidohydrolase (FAAH). FAAH is the primary catabolic enzyme for AEA, and it also regulates the contents of PEA and OEA, which do not activate CB1 and CB2. Instead, PEA and OEA apparently activate non-cannabinoid receptors, such as PPARα. Nevertheless, the role of PEA and OEA on synapsis is still unclear. NT, Neurotransmitter; DA, Dopamine; AC, Acetylcholine; VGCC, Voltage-gated calcium channel; NMDA, *N*-Methyl-[D]{.smallcaps}-aspartate; GPCR, G protein--coupled receptors; PE, Phosphatidyl ethanolamine; PC, Phosphatidylcholine; NAT, *N*-acetyltransferase; K^+^, Pottasium ion; Ca^2+^, Calcium ions; cAMP, Cyclic adenosine monophosphate; ATP, Adenosine triphosphate; AC, Adenylate cyclase; GOLF, Olfactory neuron specific-G protein involved in odorant signal transduction; Gs/i, Stimulating/Inhibitory G Protein; PK activity, Protein Kinase activity; AT, Anandamide Translocase.](fnagi-08-00081-g002){#F2}

*N*-acylethanolamides share biosynthetic and degradative mechanisms. Like AEA, PEA, and OEA are produced on demand through NAPE-PLD and catalyzed by FAAH ([@B72]; [@B67]; [@B86]; [@B78]). PEA and OEA can be also synthesized from ethanolamine and a fatty acid: palmitic acid or oleic acid, respectively ([@B71]; [@B82]) (**Figure [2](#F2){ref-type="fig"}**). Although PEA and OEA do not bind cannabinoid receptors (CB1 and CB2) ([@B72]; [@B50]; [@B82]; [@B94]), they can act as *entourage compounds*, enhancing the activity of AEA ([@B18]; [@B14]; [@B74]; [@B12]; [@B68]; [@B45]).

The biological effects of PEA and OEA are mainly mediated via the activation of the nuclear *Peroxisome Proliferator-Activated Receptor-alpha (PPARα)* ([@B72]; [@B46]; [@B91]). However, PEA and OEA might act through alternative receptors: the *transient receptor potential vaniloid type-1 (TRPV1)* ([@B95]; [@B98]; [@B3]; [@B93]), the *G protein-coupled receptors GPR55* and *GPR119* ([@B61]; [@B31]), and other peroxisome proliferator-activated receptor (PPAR) isoforms (*PPAR-δ and PPAR-γ*) ([@B26]; [@B63]). Although PEA and OEA are known to exert a protective role in response to brain injury and neuroinflammation ([@B22]), their specific role on synapsis is still unknown (**Figure [2](#F2){ref-type="fig"}**).

Endogenous Pro-homeostatic Properties of *N*-acylethanolamides
--------------------------------------------------------------

Glial cells possess endogenous homeostatic molecules, such as NAEs, which can be up-regulated in response to harmful stimuli provoking inflammation ([@B86]). *In vitro* studies have demonstrated that NAEs are produced by astrocytes ([@B96]) and PEA is synthesized and hydrolysed by microglia ([@B56]). NAEs are known to be accumulated in mammalian tissues as a result of membrane changes associated with necrosis ([@B8]). Pronounced increases in NAEs were reported in glutamate-induced excitotoxicity in cultured cortical neurons ([@B35], [@B36]). These homeostatic signals regulate cell survival upon brain damage and neuroinflammation ([@B22]).

A release of OEA (up to 242 pmol/mL), PEA (up to 120 pmol/mL), and AEA (up to 42 pmol/mL) was reported *in vivo* during human stroke, suggesting the contribution of NAEs signaling system to downstream events in the ischemic cascade ([@B79]). A significant accumulation of NAEs has been also observed in a murine model of stroke. Striatal and cortical NAEs concentrations were about 30-fold higher in the infarcted than in the non-infarcted hemisphere ([@B9]). In addition, an augmentation in PEA levels was observed in a murine model of focal cerebral ischemia ([@B25]). Moreover, an accumulation of *N-acetylethanolamide phospholipids (NAPEs)* has been registered in rat brain during post-decapitative ischemia. NAPEs are precursors for NAEs and can be formed as a stress response during neuronal injury ([@B58]). This ischemia-induced synthesis is apparently age-dependent and more pronounced in developing than in adult brain ([@B54]).

*N*-acylethanolamides might also exert a pro-homeostatic role in response to reactive gliosis and neuroinflammation in the aging brain. Recent *in vivo* studies have reported increased availability of AEA ([@B62]) and NAPE-PLD ([@B20]) during aging. PEA and OEA are up-regulated in activated cultured primary rat astrocytes after β*-amyloid (A*β*)* accumulation ([@B80]), a frequent event in the aging brain ([@B33]). In addition, *in vitro* studies have also shown an increase of PEA levels in response to neurodegeneration and reactive gliosis in *organotypic hippocampal slice cultures (OHSCs)* ([@B41]).

Endogenous synthesis of NAEs might be an adaptive response for the down-modulation of mast cells hyperactivity and consequent expression of pro-inflammatory molecules ([@B22]). This mechanism is known by the *ALIA* acronym (*Autacoid Local Inflammation Antagonism)* ([@B4]). Mast cells, non-neural and immune-related cells, are capable of crossing both compromised blood-spinal cord and blood--brain barrier in cases of CNS pathology. However, NAEs could also protect neurons against glutamate excitotoxicity ([@B88]). This finding contributed to the understanding of the pro-homeostatic role of NAEs, which represents a broader local anti-injury function (*Autacoid Local Injury Antagonism*), not limited to an autacoid reduction of inflammation. These *ALIAmides* down-regulate mast cells, protect neurons against excitotoxicity, and inhibit the spread of necrosis, thus preventing secondary neuronal damage (Esposito and Cuzzocrea).

The *entourage hypothesis* was proposed in order to explain a possible mechanism of PEA and OEA pro-homeostatic properties. This hypothesis suggests that OEA and PEA inhibit the degradation of AEA by competing with AEA for FAAH catalytic activity, thus increasing AEA levels and cytoprotective action ([@B18]; [@B14]; [@B74]; [@B12]; [@B68]; [@B45]). For instance, increases of PEA levels were reported in early stages of SCI. This augmentation could be explained by the entourage hypothesis: an increase in AEA levels and down-regulation of FAAH was also registered ([@B28]). However, another mechanism was proposed for the protective role of endogenous OEA and PEA: the activation of a nuclear receptor such as PPARα ([@B22]). The up-regulation of PEA and OEA in activated cultured primary rat astrocytes after Aβ accumulation elicited protective effects through PPARα activation, possibly to antagonize the effects of PPARα down-regulation caused by Aβ exposure. In fact, down-modulation of PPARα may represent one of the molecular mechanisms by which Aβ exerts its toxicity ([@B80]).

Therapeutic Activity of *N*-acylethanolamides
=============================================

Exogenous NAEs act apparently through *receptor pleiotropism*, i.e., interactions with different receptor targets, such as PPARα ([@B86]). PPARs are known to regulate the expression of large gene arrays, thus modulating important metabolic events ([@B10]), innate and adaptive immunity ([@B17]). *In vivo* studies have reported that the anti-inflammatory properties of PEA ([@B46]) and OEA ([@B91]) associated with neuronal protection are exerted by activating PPARα. This anti-inflammatory effect observed in wild-type mice was absent in mutant PPARα-deficient mice ([@B46]; [@B91]). PPARα-mediated neuroprotection was later replicated in several models of brain injury and neurodegeneration. Another mechanism associated with NAEs therapeutic action is down-regulation of glial activity, as it is described below and summarized in **Table [1](#T1){ref-type="table"}**.

###### 

Therapeutic effects of *N*-acylethanolamides (NAEs) in several *in vivo* and *in vitro* models of brain damage.

  Model of brain damage                                                                Therapeutic action of OEA, PEA, or AEA                                                                                                                                                                    Reference
  ------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------
  Aβ-induced astrogliosis (*In vitro*)                                                 Reduction in TNFα, COX-2, and iNOS expression                                                                                                                                                             [@B7]
                                                                                                                                                                                                                                                                                                 
  **Model of brain damage**                                                            **Therapeutic action of OEA**                                                                                                                                                                             **Reference**
                                                                                                                                                                                                                                                                                                 
  Acute cerebral ischemia (Middle cerebral artery occlusion in mice)                   Dose-dependent reduction of infarct volume and brain edema                                                                                                                                                [@B102]
                                                                                       Dose-dependent improvement in neurological dysfunction                                                                                                                                                    
                                                                                       PPARα activation                                                                                                                                                                                          
  Perinatal asphyxia (PA) (Water bath at 37°C for 20 min immediately after delivery)   Improvement in exploratory locomotion at postnatal day 30                                                                                                                                                 [@B37]
  Parkinson Disease (PD) (6-OHDA-induced striatal lesion in rats)                      Dose-dependent reduction in reactive microglia activation (OX6 expression) and oxidative response (HO-1 expression)                                                                                       [@B27]
  6-OHDA induced degeneration of substantia nigra dopamine neurons *(In vitro)*        Dose-dependent protection against toxicity and cell death                                                                                                                                                 [@B27]
  Parkinson Disease (6-OHDA-induced striatal lesion in rats)                           Dose-dependent reduction in neurotoxicity and oxidative response (HO-1 expression)                                                                                                                        [@B32]
                                                                                       Dose-dependent reduction of behavioral deficits                                                                                                                                                           
  6-OHDA induced degeneration of substantia nigra dopamine neurons *(In vitro)*        Dose-dependent protection against 6-OHDA-induced toxicity PPARα activation                                                                                                                                [@B32]
  Lipopolysaccharide-induced neuroinflammation (LPS injection in rats)                 Enhancement of the hypothermic response after LPS injection                                                                                                                                               [@B78]
                                                                                       Reduction in oxidative/nitrosative stress, IL-1β, COX-2, PGE2, and TNF-α mRNA expression                                                                                                                  
                                                                                       Disruption of anhedonia                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                 
  **Model of brain damage**                                                            **Therapeutic action of PEA**                                                                                                                                                                             **Reference**
                                                                                                                                                                                                                                                                                                 
  Lipopolysaccharide-induced neuroinflammation (LPS injection in rats)                 Enhancement of the hypothermic response after LPS injection                                                                                                                                               [@B78]
                                                                                       Reduction in oxidative/nitrosative stress, IL-1β, COX-2, and PGE2 expression                                                                                                                              
  Stroke (Middle cerebral artery occlusion in rats)                                    Reduction of edema, brain infarction, and lesion size                                                                                                                                                     [@B2]
                                                                                       Improvement in apoptosis level                                                                                                                                                                            
                                                                                       Blockage of astrocytes infiltration                                                                                                                                                                       
                                                                                       Reduction of motor deficits                                                                                                                                                                               
  Traumatic brain injury (TBI) \[Controlled cortical impact (CCI) in mice\]            Reduction of lesion size                                                                                                                                                                                  [@B1]
                                                                                       Improvement in apoptosis level                                                                                                                                                                            
                                                                                       Blockage of astrocytes infiltration                                                                                                                                                                       
                                                                                       Improvement in neurobehavioral functions                                                                                                                                                                  
  Spinal cord injury (SCI) (Compression model in mice)                                 Reduction of tissue injury                                                                                                                                                                                [@B29]
                                                                                       Reduction in the degree of apoptosis and pro-inflammatory cytokine expression                                                                                                                             
                                                                                       Recovery of motor limb function                                                                                                                                                                           
                                                                                       PPARα activation                                                                                                                                                                                          
  Spinal cord injury (Compression model in mice)                                       Reduction in mast cell infiltration and activation                                                                                                                                                        [@B24]
                                                                                       Reduction in activation of microglia and astrocytes expressing CB2                                                                                                                                        
                                                                                       Changes in the expression of neurotrophic factors and in spinal cord dopaminergic function                                                                                                                
  Peripheral neuropathy \[Chronic constriction injury (CCI) in mice\]                  Reduction of edema                                                                                                                                                                                        [@B51]
                                                                                       Reduction in macrophage infiltration                                                                                                                                                                      
                                                                                       Augmentation in myelin sheath and axonal diameter                                                                                                                                                         
                                                                                       Anti-nociception                                                                                                                                                                                          
                                                                                       PPARα activation                                                                                                                                                                                          
  Alzheimer Disease (AD) (Aβ peptide injection in mice)                                Reduction in lipid peroxidation, protein nytrosylation, iNOS induction, and caspase 3 activation expression                                                                                               [@B15]
                                                                                       Dose-dependent reduction or prevention of learning and memory impairment                                                                                                                                  
                                                                                       PPARα activation                                                                                                                                                                                          
  Alzheimer Disease (Aβ peptide injection in rats)                                     Reversion of reactive gliosis, amyloidogenesis, and tau protein hyperphosphorylation                                                                                                                      [@B82]
                                                                                       Reduction of mnestic deficits                                                                                                                                                                             
                                                                                       PPARα activation                                                                                                                                                                                          
  Aβ-induced astrogliosis (*In vitro*)                                                 Reduction in astrocytes activation                                                                                                                                                                        [@B83]
                                                                                       Improvement in neuronal survival                                                                                                                                                                          
                                                                                       PPARα activation                                                                                                                                                                                          
  Aβ-induced astrogliosis (*In vitro*)                                                 Reduction in iNOS, COX-2, nitric oxide, IL-1β, TNF-α, and PGE2 expression                                                                                                                                 [@B80]
                                                                                       PPARα activation                                                                                                                                                                                          
  Parkinson Disease (MPTP injection in mice)                                           Protection against neurotoxicity and the ensuing functional deficits, loss of TH positive neurons, and alterations of microtubule-associated protein 2a,b, dopamine transporter and nNos-positive cells   [@B23]
                                                                                       Reduction in microglial activation and the number of GFAP-positive astrocytes                                                                                                                             
                                                                                       Reversion of motor deficits                                                                                                                                                                               
                                                                                       PPARα activation                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                 

Neuroprotection in Experimental Models of Brain Injury
------------------------------------------------------

Oral OEA pre-treatment (10, 20, and 40 mg/kg, for 3 days before ischemia) could exert neuroprotective effects against acute cerebral ischemic injury in mice. Transient focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAo) for 90 min followed by reperfusion. OEA pre-treatment was associated with an improvement in neurological dysfunction and a reduction in infarct volume and brain edema. This effect was exerted via PPARα in a dose-dependent manner with 40 mg/kg as the most effective dose ([@B102]). In addition, administration of OEA (10 mg/kg) in rats subjected to perinatal asphyxia (PA) was associated with an improvement in exploratory locomotion at postnatal day 30. PA was induced by a water bath at 37°C for 20 min immediately after delivery. Currently, further research is being developed in order to study the morphological effects of OEA on PA ([@B37]). Moreover, neuroprotective properties of PEA were reported in a rat model of stroke through MCAo. PEA treatment (10 mg/kg, 1 h after ischemia and 6 h after reperfusion) reduced edema, brain infarction, and lesion size, and improved apoptosis level (assayed by Bax and Bcl-2). Infiltration of astrocytes was blocked and motor deficits were reduced ([@B2]). Similar results were reported after PEA treatment in mice subjected to an experimental model of *traumatic brain injury (TBI). Controlled cortical impact (CCI)* was performed in adult mice and produced full thickness lesions in sensorimotor cortex. PEA treatment (10 mg/kg, 1 h after TBI) could ameliorate secondary damage by reducing lesion size and blocking infiltration of astrocytes. Moreover, apoptosis level and neurobehavioral functions were improved. ([@B1]).

The effect of PEA on secondary damage induced by SCI was also tested. SCI was induced in mice by application of vascular clips to the dura mater via a four-level T5--T8 laminectomy (*compression model*). Repeated PEA administration (10 mg/kg, 30 min before, 1 and 6 h after SCI) could significantly ameliorate the recovery of motor limb function and reduce the degree of tissue injury and inflammation, pro-inflammatory cytokine expression, apoptosis, among other biomarkers. This protective action was exerted through PPARα activation ([@B29]). Further evidence supported the neuroprotective properties of PEA in SCI. SCI was induced by applying an aneurysm clip to the spinal cord in mice, thus replicating the persistence of cord compression (compression model). PEA treatment (10 mg/kg, 6 and 12 h after SCI) was able to diminish mast cell infiltration and reduce the activation of microglia and astrocytes expressing CB2 receptor after SCI. These modifications were accompanied by changes in the expression of neurotrophic factors and in spinal cord dopaminergic function ([@B24]).

Neuroprotective effects of PEA were observed in a murine model of peripheral neuropathy, which induces damage of the sciatic nerve by *chronic constriction injury (CCI).* Peripheral nerve was rescued from inflammation and structural derangement after repeated daily treatments with PEA (30 mg/kg). A reduction of edema and macrophage infiltration, and an augmentation in myelin sheath and axonal diameter were observed. In addition, anti-nociceptive effects were registered. These changes apparently occurred by a PPARα-mediated mechanism since they were absent in PPARα null mice ([@B51]).

Finally, neuroprotective properties of OEA (10 mg/kg) and PEA (10 mg/kg) were recently tested in a murine model of *LPS*-induced neuroinflammation. Both pre-treatments with OEA and PEA (10 min before LPS administration) could potentiate the hypothermic response after LPS injection, ameliorate LPS-induced oxidative/nitrosative stress, and reduce the expression of *interleukin-1*β *(IL-1*β*)*, *cyclooxygenase-2 (COX-2)*, and *prostaglandin E~2~ (PGE2)*. However, only OEA was able to reduce brain *tumor necrosis factor-α (TNF-α)* mRNA and disrupt LPS-induced anhedonia in a saccharine preference test ([@B78]).

Neuroprotection in Experimental Models of Neurodegeneration
-----------------------------------------------------------

Exogenous NAEs have exerted neuroprotective activities in experimental models of *Alzheimer disease (AD).* PEA reduced (10 mg/kg) or prevented (30 mg/kg) learning and memory impairment in mice injected intracerebroventricullarly with Aβ25--35 peptide (9 nmol). This therapeutic possibility to treat memory deficits associated with AD was apparently mediated by activation of PPARα. Besides behavioral improvement, PEA treatment (once a day, starting 3 h after Aβ25--35, for 1 or 2 weeks) reduced the expression of experimental molecular and biochemical markers induced by Aβ25--35: lipid peroxidation, protein nytrosylation, *inducible nitric oxide synthase (iNOS)* induction and caspase 3 activation ([@B15]). PEA could exert anti-inflammatory and neuroprotective effects in another experimental model of AD. Adult male rats were injected intrahippocampally with beta Aβ1--42. PEA treatment (10 mg/kg, once a day for 7 consecutive days, starting from the day of the surgery) reduced mnestic deficits and restored reactive gliosis, amyloidogenesis and tau protein hyperphosphorylation through PPARα involvement. These results suggested that PEA could have potential to alleviate the cognitive symptoms and to modify disease progression ([@B82]).

Palmitoylethanolamide treatment results in a decreased Aβ-induced astrocyte activation and improves neuronal survival via PPARα. Primary rat mixed neuroglial co-cultures and organotypic hippocampal slices were challenged with Aβ1--42 and treated with PEA. The findings of this study reveal the neuroprotective effect of reactive gliosis reduction ([@B83]). Similar *in vitro* studies from the same laboratory were aimed at assessing the effect of exogenous PEA on the production of pro-inflammatory molecules induced by Aβ: iNOS, COX-2, nitric oxide, IL-1β, TNF-α, and PGE2. PEA could blunt the expression and release of all the pro-inflammatory factors. These effects were attenuated by a PPARα antagonist, suggesting that the anti-inflammatory properties of PEA may be mediated by this nuclear receptor ([@B80]). Moreover, exogenous OEA, PEA, and AEA have shown an anti-inflammatory response *in vitro* by preventing the increase in TNFα, COX-2, and iNOS induced by the pathologic form of Aβ. No additive effect was found when the three NAEs were added together to the cell cultures ([@B7]).

Neuroprotective effects of NAEs were encountered in experimental models of *Parkinson disease (PD)*. Mice were treated with *1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine (MPTP)*, which mimics biochemical and cellular changes that occur in idiopathic PD. Protection against MPTP-induced loss of *tyrosine hydroxylase (TH)* positive neurons in the substantia nigra was observed in mice treated with PEA (10 mg/kg). Chronic treatment was initiated 24 h after MPTP injection. Mice subjected to PEA treatment were also protected against the alterations of microtubule-associated protein 2a,b, dopamine transporter and nNos-positive cells in the substantia nigra. In addition, a reduction in microglial activation and the number of GFAP-positive astrocytes was observed, and MPTP-associated motor deficits were reversed. Furthermore, PEA was apparently protective against neurotoxicity and the ensuing functional deficits. This neuroprotective effect was exerted by activating PPARα ([@B23]). Neuroprotective properties of OEA were also tested on experimental models of PD. OEA exerted cytoprotective effects both *in vitro* and *in vivo* models of *6-hydroxydopamine (6-OHDA)*-induced degeneration of substantia nigra dopaminergic neurons. OEA could exert a reduction in heme oxygenase-1 (oxidation marker) and OX6 (reactive microglia marker) *in vivo*, and protection against toxicity and cell death *in vitro*. However, these effects were U-shaped partial and dose-dependent, suggesting toxicity due to high drug concentration or an activation of opposing intracellular pathways by different OEA doses ([@B27]). OEA-mediated neuroprotection of the nigrostriatal system was supported by a recent study. The *in vivo* model consisted of the intrastriatal infusion of 6-OHDA, which generates Parkinsonian symptoms. Neurotoxicity and behavioral deficits were less severe in the animals treated with the highest dose of OEA (5 mg/kg). In addition, 6-OHDA enhanced *heme oxygenase 1 (HO-1)* content was blocked by OEA (5 mg/kg). *In vitro*, OEA (0.5 and 1 μM) exerted significant neuroprotection on cultured nigral neurons via PPARα activation ([@B32]).

Concluding Remarks and Perspectives
===================================

Glial cells are apparently responsible for producing NAEs ([@B96]; [@B56]), which constitute a homeostatic signaling system in response to brain damage and inflammation ([@B22]; [@B86]). Accordingly, an augmentation of NAEs levels has been reported in brain aging ([@B62]), Aβ-induced astrogliosis ([@B80]), neurodegeneration ([@B41]), SCI ([@B28]), stroke ([@B79]; [@B9]), and cerebral ischemia ([@B58]; [@B25]). The Autacoid Local Injury Antagonism ([@B88]) and the entourage effect ([@B18]; [@B14]; [@B74]; [@B12]; [@B68]; [@B45]) were proposed as mechanisms of NAEs homeostatic functions. However, in some pathological scenarios, NAEs endogenous synthesis is inadequate to control the inflammatory cascade ([@B86]). When there is chronic non-resolving inflammation, dysfunctional reactive gliosis becomes detrimental and glial activity might not be beneficial any longer ([@B64]). Therefore, exogenous NAEs may exert neuroprotective effects by down-regulating astrocytes ([@B1],[@B2]; [@B83], [@B82]), microglia ([@B27]), or both microglia and astrocytes ([@B24], [@B23]). In this sense, glia constitutes a target for exogenous NAEs ([@B81]; [@B86]). Moreover, inhibition of endogenous NAEs degradation could represent a complementary therapeutic approach for neuroinflammation. Potential selective *N-acylethanolamide-hydrolyzing acid amidase (NAAA)* inhibitors have shown anti-inflammatory effects ([@B90]; [@B77]; [@B44]; [@B100]). This fact supports the involvement of NAEs in the control of inflammation ([@B66]). However, future research should attempt to clarify the role of glial cells in brain injury, and their interaction with NAEs.

Neuroprotection exerted by exogenous PEA and OEA was observed in several *in vivo* and *in vitro* models of brain injury and neurodegenerative diseases ([@B29]; [@B27]; [@B24], [@B23]; [@B80], [@B83], [@B82]; [@B1],[@B2]; [@B7]; [@B15]; [@B102]; [@B51]; [@B32]; [@B78]). However, the entourage effect was not referred as a mechanism of neuroprotection. In addition, a group of researchers has studied this issue in particular. PEA- mediated neuroprotective effects in dentate gyrus granule cells in excitotoxically lesioned OHSCs ([@B42]) were not exerted by AEA ([@B43]). Therefore, the entourage hypothesis could not explain PEA neuroprotective action, which was actually mediated by PPARα activation ([@B42]).

Peroxisome proliferator-activated receptor-α appears as a crucial site at which PEA and OEA generate their neuroprotective actions. Exogenous PEA and OEA have repeatedly exerted neuroprotective effects by activating the anti-inflammatory nuclear receptor PPARα ([@B46]; [@B91]; [@B29]; [@B80], [@B83], [@B82]; [@B15]; [@B23]; [@B102]; [@B51]; [@B32]). Additionally, endogenous PEA and OEA have demonstrated protective effects via PPARα in activated cultured primary rat astrocytes subjected to Aβ accumulation ([@B80]) In fact, a recent hypothesis proposes that PPARs play a crucial role on metabolic and inflammatory compensation of astrogliosis and may interact with ligands on different metabolic pathways in order to supply energy to the neurons ([@B39]).

Moreover, some studies on neuroprotective effects of exogenous PEA and OEA revealed a co-occurrence between PPARα activation and down-regulation of glia ([@B23]; [@B83], [@B82]). Additionally, it was hypothesized that PEA-mediated PPARα activation could reduce significantly the number of microglial cells and counteract secondary neuronal damage of dentate gyrus granule cells in excitotoxically lesioned OHSCs ([@B42]). Further studies might help to elucidate whether NAEs-mediated PPARα activation is capable of counteracting glial activation.
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